Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.60 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030256 | 0.93 | GUCY1A1 (0.63) | GUCY1A1GUCY1B1KEAP1NFE2L2 | |
| SCHEMBL3038297 | 0.92 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1 | |
| SCHEMBL3029192 | 0.92 | GUCY1A1 (0.68) | GUCY1A1GUCY1B1 | |
| SCHEMBL211585 | 0.91 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1 | |
| SCHEMBL3031396 | 0.89 | GUCY1A1 (0.65) | GUCY1A1GUCY1B1 | |
| SCHEMBL3041079 | 0.88 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1 | |
| SCHEMBL3034275 | 0.88 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KEAP1NFE2L2 | |
| SCHEMBL3041491 | 0.88 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1 | |
| SCHEMBL3033985 | 0.86 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1 | |
| SCHEMBL3035138 | 0.85 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | GUCY1A1 2/4885GUCY1B1 1/4885KEAP1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.